Aspen Aerogels, Inc. — Q1 2015 Form 10-Q
Reporting period: Three months ended March 31, 2015; comparisons are to Q1 2014 unless noted. Aspen designs and manufactures aerogel insulation and also performs contract research. Amounts below are in U.S. dollars; financial statement amounts are in millions unless stated otherwise.
Financial results and key metrics
| Metric | Q1 2015 | Q1 2014 / comparison |
|---|---|---|
| Total revenue | $23.5 | $22.4; up 5% |
| Product revenue | $23.2 | $21.5; up 8% |
| Research services revenue | $0.3 | $0.9; down 67% |
| Gross profit / margin | $4.5 / 19% | $3.3 / 15% |
| Operating loss | $(2.7) | $(2.9) |
| Net loss | $(2.8) | $(19.0) |
| Adjusted EBITDA, non-GAAP | $0.7 | $0.1 |
| Operating cash flow | $(3.7) | $0.8 provided |
| Capital expenditures | $10.5 | $1.1 |
- Product shipments were 8.78 million square feet, essentially flat with 8.80 million. Average selling price increased 8.2% to $2.64 per square foot, reflecting 2014 price increases and a shift toward higher-priced products.
- Operating expenses were $7.3 million, up from $6.2 million. General and administrative expense rose 33% to $3.6 million, primarily from higher stock compensation and public-company insurance and professional fees.
- Cash and cash equivalents were $33.0 million at March 31, down from $49.7 million at year-end; marketable securities were $2.5 million. Total assets were $141.5 million and stockholders’ equity was $122.2 million.
- Total liabilities were $19.3 million. Debt was limited to approximately $0.1 million of capital leases; there were no revolving-credit borrowings. The $20 million facility had $10.9 million effectively available after borrowing-base limits and $1.4 million of letters of credit. The company reported covenant compliance.
Material changes and operating developments
- Revenue growth came from pricing and product mix, not higher shipment volume. Research services revenue fell as the company worked on four contracts versus eight a year earlier; management cited limits on eligibility for certain federal contract awards.
- Gross margin improved to 19% from 15%, supported by higher prices, favorable mix, and improved manufacturing yields. Product cost of revenue was 81% of product revenue versus 86% a year earlier.
- The third East Providence production line was completed and placed in service in March. Its construction cost was $31.8 million and it is expected to add 10–11 million square feet of annual nameplate capacity, bringing estimated total capacity to 50–55 million square feet, depending on product mix.
- Q1 2014 net loss included $16.2 million of interest expense, principally fair-value adjustments on debt that converted to equity or was repaid following the June 2014 IPO. Consequently, the year-over-year reduction in net loss is not solely an indicator of operating improvement. Reported per-share loss comparisons are also distorted by the IPO and prior reverse stock split; the filing reports $(0.12) per share in 2015 and $(6,066.56) in 2014.
Outlook, risks, and contingencies
- Management anticipated continued revenue growth, higher gross profit, and improving operating cash flows, while expecting significant capital expenditures through 2017 to expand capacity, including development of a second U.S. plant. Funding sources discussed include cash, operating cash flow, government grants, debt, and potentially equity financing; the filing gives no specific revenue or earnings guidance.
- Management expected manufacturing costs to rise in the near term as the third line operates, but said higher production volumes, productivity, and yields should support margin improvement. It also expected continued investment and increased expenses for research and development, sales and marketing, and administration.
- Key risks include execution and funding of capacity expansion, demand and product mix, manufacturing costs and yields, limited eligibility for certain government research contracts, and access to additional financing. The company cautioned that forward-looking statements are uncertain and that Q1 results are not necessarily indicative of full-year results.
- No material legal proceedings or probable loss contingencies requiring accrual were reported. Management said there were no material changes to the risk factors in its 2014 Form 10-K. No off-balance-sheet arrangements were reported.
Important facts for investors to verify
- Whether the new production line achieves expected capacity, utilization, yields, and cost improvements—and whether this translates into sustained gross-margin gains.
- Whether flat shipment volume persists and whether price increases and favorable product mix can support revenue growth.
- How operating cash use and planned expansion spending affect liquidity, and whether additional financing will be required to build the second plant.
- Whether research-contract eligibility constraints continue to reduce research services revenue.
- The comparability of reported net loss and per-share figures across periods, given the 2014 debt fair-value charges and IPO-related capital-structure changes.